Antisense & RNAi Therapeutics – A Global Market Overview
Antisense & RNAi Therapeutics Market Trends and Outlook
Antisense and RNA interference (RNAi) therapeutics are novel approaches to inhibit gene expression to treat diseases. Antisense therapy utilizes synthetic nucleic acids called antisense oligonucleotides (ASOs) that bind to specific messenger RNA (mRNA) sequences, effectively silencing disease-associated genes. RNAi employs double-stranded RNA (dsRNA) to produce small interfering RNA (siRNA) and microRNA (miRNA) that degrade target mRNAs, thereby preventing protein production. Both approaches are under development for conditions such as cancer, neurodegenerative disorders, cardiometabolic disorders, and ocular diseases. While they offer precise gene suppression crucial for treating chronic and rare diseases, challenges remain in delivering ASOs to specific tissues. Advances in nucleic acid technologies continue to broaden their therapeutic applications in oncology, genetic disorders, and infectious diseases.
The global market for Antisense & RNAi Therapeutics is estimated at US$5.4 billion in 2024 and is anticipated to post a CAGR of 17.8% during the 2024-2030 analysis period and stand at a projected US$14.4 billion by 2030.
The Antisense & RNAi therapeutics market growth is primarily driven by advancements in drug delivery technologies, like lipid nanoparticles and conjugate systems, which improve the stability and cellular uptake of RNA-based drugs. Additionally, the increasing occurrence of chronic and genetic diseases, along with the ability of these therapies to target disease-specific genes, has spurred the demand. The market is expanding further due to the increased focus on research and development in rare diseases like Amyloid Transthyretin (ATTR) amyloidosis and Spinal Muscular Atrophy (SMA). This leads to the potential for orphan drug designations and associated incentives.
Antisense & RNAi Therapeutics Regional Market Analysis
North America dominates the global Antisense & RNAi therapeutics market, with an estimated 52.6% of the market share in 2024. This dominance is driven by robust pharmaceutical and biotechnology sectors, significant investments in research and development, and the presence of major pharmaceutical companies and research institutions that enhance access to advanced treatments, supported by a robust healthcare infrastructure promoting early rare disease screening. In contrast, the Asia Pacific region is projected to register the fastest CAGR of 18.9% during the forecast period from 2024 to 2030, fueled by emerging markets such as China and India. These countries are enhancing generic drug manufacturing and promoting local biotech innovation, leading to more affordable therapies, and attracting substantial investments from global pharmaceutical firms.
Antisense & RNAi Therapeutics Market Analysis by Technology
The Antisense RNA segment is the largest market, with an estimated share of 64.1% in 2024, driven by its application in cardiovascular, respiratory, neurodegenerative, and genetic disorders. Its precision in regulating gene and protein expression enhances therapies and spurs ongoing research. Successful clinical trials and FDA approvals validate antisense therapies' efficacy, attracting investment and increasing demand due to the rising prevalence of these disorders. Meanwhile, the RNA Interference (RNAi) technology segment is anticipated to record the fastest CAGR of 19% during the analysis period 2024-2030, with applications in targeting cancer-related genes and treating bacterial, viral, and parasitic diseases, reflecting the technology's versatility and potential to address unmet medical needs.
Antisense & RNAi Therapeutics Market Analysis by Route of Administration
The intrathecal injections segment leads the market in 2024 with a share of 36.9%, as this method allows for effective pain management and spasticity reduction with smaller doses directly delivered to the cerebrospinal fluid. Despite being invasive, intrathecal drug delivery has a low complication rate and is widely used for chemotherapy and infection treatment post-neurosurgery. In contrast, the subcutaneous injection segment is projected to record the fastest CAGR of 19.3% from 2024 to 2030, offering a convenient and low-risk alternative to intravenous administration. This method provides flexibility in injection sites and employs smaller needles, potentially reducing patient discomfort and promoting segment growth.
Antisense & RNAi Therapeutics Market Analysis by Application
The neurodegenerative disorders segment dominates the market with an estimated share of 27.1% in 2024, primarily affecting the elderly and prompting significant biomedical research for therapeutic development. The increasing number of RNA-based techniques enhances the ability to target various disease-associated genes, making it a key focus for industry players. Conversely, the genetic disorders segment is projected to grow at the fastest CAGR of 19.3% during the forecast period 2024-2030, driven by innovations in RNA vaccines and gene therapy. The application of novel RNA editing methods in gene therapy shows promise for effectively treating genetic disorders.
Antisense & RNAi Therapeutics Market Report Scope
This global report on Antisense & RNAi Therapeutics analyzes the market based on technology, route of administration and applications. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.
Key Metrics
Historical Period: 2021-2023
Base Year: 2023
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 10+
Antisense & RNAi Therapeutics Market by Geographic Region
Antisense and RNA interference (RNAi) therapeutics are novel approaches to inhibit gene expression to treat diseases. Antisense therapy utilizes synthetic nucleic acids called antisense oligonucleotides (ASOs) that bind to specific messenger RNA (mRNA) sequences, effectively silencing disease-associated genes. RNAi employs double-stranded RNA (dsRNA) to produce small interfering RNA (siRNA) and microRNA (miRNA) that degrade target mRNAs, thereby preventing protein production. Both approaches are under development for conditions such as cancer, neurodegenerative disorders, cardiometabolic disorders, and ocular diseases. While they offer precise gene suppression crucial for treating chronic and rare diseases, challenges remain in delivering ASOs to specific tissues. Advances in nucleic acid technologies continue to broaden their therapeutic applications in oncology, genetic disorders, and infectious diseases.
The global market for Antisense & RNAi Therapeutics is estimated at US$5.4 billion in 2024 and is anticipated to post a CAGR of 17.8% during the 2024-2030 analysis period and stand at a projected US$14.4 billion by 2030.
The Antisense & RNAi therapeutics market growth is primarily driven by advancements in drug delivery technologies, like lipid nanoparticles and conjugate systems, which improve the stability and cellular uptake of RNA-based drugs. Additionally, the increasing occurrence of chronic and genetic diseases, along with the ability of these therapies to target disease-specific genes, has spurred the demand. The market is expanding further due to the increased focus on research and development in rare diseases like Amyloid Transthyretin (ATTR) amyloidosis and Spinal Muscular Atrophy (SMA). This leads to the potential for orphan drug designations and associated incentives.
Antisense & RNAi Therapeutics Regional Market Analysis
North America dominates the global Antisense & RNAi therapeutics market, with an estimated 52.6% of the market share in 2024. This dominance is driven by robust pharmaceutical and biotechnology sectors, significant investments in research and development, and the presence of major pharmaceutical companies and research institutions that enhance access to advanced treatments, supported by a robust healthcare infrastructure promoting early rare disease screening. In contrast, the Asia Pacific region is projected to register the fastest CAGR of 18.9% during the forecast period from 2024 to 2030, fueled by emerging markets such as China and India. These countries are enhancing generic drug manufacturing and promoting local biotech innovation, leading to more affordable therapies, and attracting substantial investments from global pharmaceutical firms.
Antisense & RNAi Therapeutics Market Analysis by Technology
The Antisense RNA segment is the largest market, with an estimated share of 64.1% in 2024, driven by its application in cardiovascular, respiratory, neurodegenerative, and genetic disorders. Its precision in regulating gene and protein expression enhances therapies and spurs ongoing research. Successful clinical trials and FDA approvals validate antisense therapies' efficacy, attracting investment and increasing demand due to the rising prevalence of these disorders. Meanwhile, the RNA Interference (RNAi) technology segment is anticipated to record the fastest CAGR of 19% during the analysis period 2024-2030, with applications in targeting cancer-related genes and treating bacterial, viral, and parasitic diseases, reflecting the technology's versatility and potential to address unmet medical needs.
Antisense & RNAi Therapeutics Market Analysis by Route of Administration
The intrathecal injections segment leads the market in 2024 with a share of 36.9%, as this method allows for effective pain management and spasticity reduction with smaller doses directly delivered to the cerebrospinal fluid. Despite being invasive, intrathecal drug delivery has a low complication rate and is widely used for chemotherapy and infection treatment post-neurosurgery. In contrast, the subcutaneous injection segment is projected to record the fastest CAGR of 19.3% from 2024 to 2030, offering a convenient and low-risk alternative to intravenous administration. This method provides flexibility in injection sites and employs smaller needles, potentially reducing patient discomfort and promoting segment growth.
Antisense & RNAi Therapeutics Market Analysis by Application
The neurodegenerative disorders segment dominates the market with an estimated share of 27.1% in 2024, primarily affecting the elderly and prompting significant biomedical research for therapeutic development. The increasing number of RNA-based techniques enhances the ability to target various disease-associated genes, making it a key focus for industry players. Conversely, the genetic disorders segment is projected to grow at the fastest CAGR of 19.3% during the forecast period 2024-2030, driven by innovations in RNA vaccines and gene therapy. The application of novel RNA editing methods in gene therapy shows promise for effectively treating genetic disorders.
Antisense & RNAi Therapeutics Market Report Scope
This global report on Antisense & RNAi Therapeutics analyzes the market based on technology, route of administration and applications. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.
Key Metrics
Historical Period: 2021-2023
Base Year: 2023
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 10+
Antisense & RNAi Therapeutics Market by Geographic Region
- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World
- Antisense RNA
- RNA Interference
- Intrathecal
- Intravenous
- Subcutaneous
- Others (Including Topical, Pulmonary, Transdermal, Oral, and Ophthalmic Administration)
- Neurodegenerative Disorders
- Oncology
- Cardiometabolic & Renal Disorders
- Genetic Disorders
- Infectious Diseases
- Respiratory Disorders
- Other Applications (Including Ocular, Muscle, Skin, Autoimmune, Hematological Disorders, and Others)
PART A: GLOBAL MARKET PERSPECTIVE
1. INTRODUCTION
Product Outline
Antisense and RNAi Therapeutics Defined
Antisense and RNAi Therapeutic Technologies
Antisense RNA
RNA Interference
Antisense and RNAi Therapeutic Route of Administration
Intrathecal
Intravenous
Subcutaneous
Others (Including Topical, Pulmonary, Transdermal, Oral, and Ophthalmic Administration)
Antisense and RNAi Therapeutic Applications
Neurodegenerative Disorders
Oncology
Cardiometabolic & Renal Disorders
Genetic Disorders
Infectious Diseases
Respiratory Disorders
Other Applications (Including Ocular, Muscle, Skin, Autoimmune, Hematological Disorders, and Others)
2. Key Market Trends
3. Key Global Players
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma Corporation
Benitec Biopharma Inc.
GSK plc
Ionis Pharmaceuticals, Inc.
Olix Pharmaceuticals, Inc.
Percheron Therapeutics Limited
Sanofi S.A.
Sarepta Therapeutics, Inc.
Silence Therapeutics plc
4. Key Business & Product Trends
5. Global Market Overview
Global Antisense and RNAi Therapeutics Market Overview by Technology
Antisense and RNAi Therapeutics Technology Market Overview by Global Region
Antisense RNA
RNA Interference
Global Antisense and RNAi Therapeutics Market Overview by Route of Administration
Antisense and RNAi Therapeutics Route of Administration Market Overview by Global Region
Intrathecal
Intravenous
Subcutaneous
Others
Global Antisense and RNAi Therapeutics Market Overview by Application
Antisense and RNAi Therapeutics Application Market Overview by Global Region
Neurodegenerative Disorders
Oncology
Cardiometabolic & Renal Disorders
Genetic Disorders
Infectious Diseases
Respiratory Disorders
Other Applications
PART B: REGIONAL MARKET PERSPECTIVE
Global Antisense and RNAi Therapeutics Market Overview by Geographic Region
REGIONAL MARKET OVERVIEW
6. North America
North American Antisense and RNAi Therapeutics Market Overview by Geographic Region
North American Antisense and RNAi Therapeutics Market Overview by Technology
North American Antisense and RNAi Therapeutics Market Overview by Route of Administration
North American Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of North American Antisense and RNAi Therapeutics Market
The United States
United States Antisense and RNAi Therapeutics Market Overview by Technology
United States Antisense and RNAi Therapeutics Market Overview by Route of Administration
United States Antisense and RNAi Therapeutics Market Overview by Application
Canada
Canadian Antisense and RNAi Therapeutics Market Overview by Technology
Canadian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Canadian Antisense and RNAi Therapeutics Market Overview by Application
Mexico
Mexican Antisense and RNAi Therapeutics Market Overview by Technology
Mexican Antisense and RNAi Therapeutics Market Overview by Route of Administration
Mexican Antisense and RNAi Therapeutics Market Overview by Application
7. Europe
European Antisense and RNAi Therapeutics Market Overview by Geographic Region
European Antisense and RNAi Therapeutics Market Overview by Technology
European Antisense and RNAi Therapeutics Market Overview by Route of Administration
European Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of European Antisense and RNAi Therapeutics Market
Germany
German Antisense and RNAi Therapeutics Market Overview by Technology
German Antisense and RNAi Therapeutics Market Overview by Route of Administration
German Antisense and RNAi Therapeutics Market Overview by Application
France
French Antisense and RNAi Therapeutics Market Overview by Technology
French Antisense and RNAi Therapeutics Market Overview by Route of Administration
French Antisense and RNAi Therapeutics Market Overview by Application
The United Kingdom
United Kingdom Antisense and RNAi Therapeutics Market Overview by Technology
United Kingdom Antisense and RNAi Therapeutics Market Overview by Route of Administration
United Kingdom Antisense and RNAi Therapeutics Market Overview by Application
Italy
Italian Antisense and RNAi Therapeutics Market Overview by Technology
Italian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Italian Antisense and RNAi Therapeutics Market Overview by Application
Spain
Spanish Antisense and RNAi Therapeutics Market Overview by Technology
Spanish Antisense and RNAi Therapeutics Market Overview by Route of Administration
Spanish Antisense and RNAi Therapeutics Market Overview by Application
Rest of Europe
Rest of Europe Antisense and RNAi Therapeutics Market Overview by Technology
Rest of Europe Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of Europe Antisense and RNAi Therapeutics Market Overview by Application
8. Asia-Pacific
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Geographic Region
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Technology
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Route of Administration
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of Asia-Pacific Antisense and RNAi Therapeutics Market
Japan
Japanese Antisense and RNAi Therapeutics Market Overview by Technology
Japanese Antisense and RNAi Therapeutics Market Overview by Route of Administration
Japanese Antisense and RNAi Therapeutics Market Overview by Application
China
Chinese Antisense and RNAi Therapeutics Market Overview by Technology
Chinese Antisense and RNAi Therapeutics Market Overview by Route of Administration
Chinese Antisense and RNAi Therapeutics Market Overview by Application
India
Indian Antisense and RNAi Therapeutics Market Overview by Technology
Indian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Indian Antisense and RNAi Therapeutics Market Overview by Application
South Korea
South Korean Antisense and RNAi Therapeutics Market Overview by Technology
South Korean Antisense and RNAi Therapeutics Market Overview by Route of Administration
South Korean Antisense and RNAi Therapeutics Market Overview by Application
Rest of Asia-Pacific
Rest of Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Technology
Rest of Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Application
9. South America
South American Antisense and RNAi Therapeutics Market Overview by Geographic Region
South American Antisense and RNAi Therapeutics Market Overview by Technology
South American Antisense and RNAi Therapeutics Market Overview by Route of Administration
South American Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of Asia-Pacific Antisense and RNAi Therapeutics Market
Brazil
Brazilian Antisense and RNAi Therapeutics Market Overview by Technology
Brazilian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Brazilian Antisense and RNAi Therapeutics Market Overview by Application
Argentina
Argentine Antisense and RNAi Therapeutics Market Overview by Technology
Argentine Antisense and RNAi Therapeutics Market Overview by Route of Administration
Argentine Antisense and RNAi Therapeutics Market Overview by Application
Rest of South America
Rest of South American Antisense and RNAi Therapeutics Market Overview by Technology
Rest of South American Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of South American Antisense and RNAi Therapeutics Market Overview by Application
10. Rest of World
Rest of World Antisense and RNAi Therapeutics Market Overview by Technology
Rest of World Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of World Antisense and RNAi Therapeutics Market Overview by Application
PART C: GUIDE TO THE INDUSTRY
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK
1. INTRODUCTION
Product Outline
Antisense and RNAi Therapeutics Defined
Antisense and RNAi Therapeutic Technologies
Antisense RNA
RNA Interference
Antisense and RNAi Therapeutic Route of Administration
Intrathecal
Intravenous
Subcutaneous
Others (Including Topical, Pulmonary, Transdermal, Oral, and Ophthalmic Administration)
Antisense and RNAi Therapeutic Applications
Neurodegenerative Disorders
Oncology
Cardiometabolic & Renal Disorders
Genetic Disorders
Infectious Diseases
Respiratory Disorders
Other Applications (Including Ocular, Muscle, Skin, Autoimmune, Hematological Disorders, and Others)
2. Key Market Trends
3. Key Global Players
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma Corporation
Benitec Biopharma Inc.
GSK plc
Ionis Pharmaceuticals, Inc.
Olix Pharmaceuticals, Inc.
Percheron Therapeutics Limited
Sanofi S.A.
Sarepta Therapeutics, Inc.
Silence Therapeutics plc
4. Key Business & Product Trends
5. Global Market Overview
Global Antisense and RNAi Therapeutics Market Overview by Technology
Antisense and RNAi Therapeutics Technology Market Overview by Global Region
Antisense RNA
RNA Interference
Global Antisense and RNAi Therapeutics Market Overview by Route of Administration
Antisense and RNAi Therapeutics Route of Administration Market Overview by Global Region
Intrathecal
Intravenous
Subcutaneous
Others
Global Antisense and RNAi Therapeutics Market Overview by Application
Antisense and RNAi Therapeutics Application Market Overview by Global Region
Neurodegenerative Disorders
Oncology
Cardiometabolic & Renal Disorders
Genetic Disorders
Infectious Diseases
Respiratory Disorders
Other Applications
PART B: REGIONAL MARKET PERSPECTIVE
Global Antisense and RNAi Therapeutics Market Overview by Geographic Region
REGIONAL MARKET OVERVIEW
6. North America
North American Antisense and RNAi Therapeutics Market Overview by Geographic Region
North American Antisense and RNAi Therapeutics Market Overview by Technology
North American Antisense and RNAi Therapeutics Market Overview by Route of Administration
North American Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of North American Antisense and RNAi Therapeutics Market
The United States
United States Antisense and RNAi Therapeutics Market Overview by Technology
United States Antisense and RNAi Therapeutics Market Overview by Route of Administration
United States Antisense and RNAi Therapeutics Market Overview by Application
Canada
Canadian Antisense and RNAi Therapeutics Market Overview by Technology
Canadian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Canadian Antisense and RNAi Therapeutics Market Overview by Application
Mexico
Mexican Antisense and RNAi Therapeutics Market Overview by Technology
Mexican Antisense and RNAi Therapeutics Market Overview by Route of Administration
Mexican Antisense and RNAi Therapeutics Market Overview by Application
7. Europe
European Antisense and RNAi Therapeutics Market Overview by Geographic Region
European Antisense and RNAi Therapeutics Market Overview by Technology
European Antisense and RNAi Therapeutics Market Overview by Route of Administration
European Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of European Antisense and RNAi Therapeutics Market
Germany
German Antisense and RNAi Therapeutics Market Overview by Technology
German Antisense and RNAi Therapeutics Market Overview by Route of Administration
German Antisense and RNAi Therapeutics Market Overview by Application
France
French Antisense and RNAi Therapeutics Market Overview by Technology
French Antisense and RNAi Therapeutics Market Overview by Route of Administration
French Antisense and RNAi Therapeutics Market Overview by Application
The United Kingdom
United Kingdom Antisense and RNAi Therapeutics Market Overview by Technology
United Kingdom Antisense and RNAi Therapeutics Market Overview by Route of Administration
United Kingdom Antisense and RNAi Therapeutics Market Overview by Application
Italy
Italian Antisense and RNAi Therapeutics Market Overview by Technology
Italian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Italian Antisense and RNAi Therapeutics Market Overview by Application
Spain
Spanish Antisense and RNAi Therapeutics Market Overview by Technology
Spanish Antisense and RNAi Therapeutics Market Overview by Route of Administration
Spanish Antisense and RNAi Therapeutics Market Overview by Application
Rest of Europe
Rest of Europe Antisense and RNAi Therapeutics Market Overview by Technology
Rest of Europe Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of Europe Antisense and RNAi Therapeutics Market Overview by Application
8. Asia-Pacific
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Geographic Region
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Technology
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Route of Administration
Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of Asia-Pacific Antisense and RNAi Therapeutics Market
Japan
Japanese Antisense and RNAi Therapeutics Market Overview by Technology
Japanese Antisense and RNAi Therapeutics Market Overview by Route of Administration
Japanese Antisense and RNAi Therapeutics Market Overview by Application
China
Chinese Antisense and RNAi Therapeutics Market Overview by Technology
Chinese Antisense and RNAi Therapeutics Market Overview by Route of Administration
Chinese Antisense and RNAi Therapeutics Market Overview by Application
India
Indian Antisense and RNAi Therapeutics Market Overview by Technology
Indian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Indian Antisense and RNAi Therapeutics Market Overview by Application
South Korea
South Korean Antisense and RNAi Therapeutics Market Overview by Technology
South Korean Antisense and RNAi Therapeutics Market Overview by Route of Administration
South Korean Antisense and RNAi Therapeutics Market Overview by Application
Rest of Asia-Pacific
Rest of Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Technology
Rest of Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of Asia-Pacific Antisense and RNAi Therapeutics Market Overview by Application
9. South America
South American Antisense and RNAi Therapeutics Market Overview by Geographic Region
South American Antisense and RNAi Therapeutics Market Overview by Technology
South American Antisense and RNAi Therapeutics Market Overview by Route of Administration
South American Antisense and RNAi Therapeutics Market Overview by Application
Country-wise Analysis of Asia-Pacific Antisense and RNAi Therapeutics Market
Brazil
Brazilian Antisense and RNAi Therapeutics Market Overview by Technology
Brazilian Antisense and RNAi Therapeutics Market Overview by Route of Administration
Brazilian Antisense and RNAi Therapeutics Market Overview by Application
Argentina
Argentine Antisense and RNAi Therapeutics Market Overview by Technology
Argentine Antisense and RNAi Therapeutics Market Overview by Route of Administration
Argentine Antisense and RNAi Therapeutics Market Overview by Application
Rest of South America
Rest of South American Antisense and RNAi Therapeutics Market Overview by Technology
Rest of South American Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of South American Antisense and RNAi Therapeutics Market Overview by Application
10. Rest of World
Rest of World Antisense and RNAi Therapeutics Market Overview by Technology
Rest of World Antisense and RNAi Therapeutics Market Overview by Route of Administration
Rest of World Antisense and RNAi Therapeutics Market Overview by Application
PART C: GUIDE TO THE INDUSTRY
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK
